Novartis logo
Novartis
NVSEF | OTC
Chart Builder DCF Calculator
$134.20
-$6.73 (-4.78%)
At close: Oct 2, 2026, 3:14 PM ET

Novartis Company Profile

Company profile explained

Company Profile

Novartis AG, a global pharmaceutical enterprise established in 1996 and based in Basel, Switzerland, is engaged in the entire lifecycle of healthcare products, from research and development to manufacturing and worldwide commercialization. The company's operations are divided into two main divisions: Innovative Medicines and Sandoz. The Innovative Medicines segment is dedicated to providing advanced prescription medications to both patients and healthcare professionals. Its extensive product portfolio covers a wide range of therapeutic areas, including ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory conditions, cardiovascular health, renal diseases, and metabolism. Conversely, the Sandoz segment specializes in a comprehensive array of generic and biosimilar products. This involves the creation, production, and distribution of finished dosage form medicines, as well as active ingredients and small molecule pharmaceuticals for external partners. Sandoz also supplies generic drugs for retail, anti-infectives, and crucial active pharmaceutical ingredients (APIs) and intermediates, particularly antibiotics. Additionally, this division is involved in developing protein-based and other biotechnology products, such as biosimilars, and offers biotechnology manufacturing services. Novartis AG also pursues strategic collaborations. It has a licensing and collaboration agreement with Alnylam Pharmaceuticals concerning the development, production, and commercialization of inclisiran. Moreover, the company maintains a clinical partnership with Kura Oncology, Inc. to assess the combined efficacy of Tipifarnib and Alpelisib in treating head and neck squamous cell carcinoma patients.

Key Executives

Name Position
Vasant Narasimhan Chief Executive Officer
Mukul Mehta Chief Financial Officer
Evan Beckman Global Head of Translational Medicine at Novartis Institute for BioMedical Research
Karen L. Hale Chief Legal & Compliance Officer
Patrick Horber President of International
Paul Penepent Head of Group Financial Reporting and Accounting
Robert Kowalski Chief People & Organization Officer
Sloan Simpson Global Head of Investor Relations
Steffen Lang President of Operations
Victor Bulto President of US
Novartis
Novartis logo
Country Switzerland
IPO Date Apr 26, 2010
Industry Drug Manufacturers - General
Sector Healthcare
Employees 75,267
CEO Vasant Narasimhan

Contact Details

Lichtstrasse 35 Basel, BS 4056 Switzerland

Stock Details

Ticker Symbol NVSEF
Exchange OTC
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001114448
CUSIP Number n/a
ISIN Number CH0012005267
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.